Zipalertinib (CLN-081)

Name: Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Pharmacokinetics
Published: 2026-09-14T15:39:06-04:00

EGFR exon 20 insertion-mutated non-small-cell lung cancer

Also known as TAS6417

Manufacturer: Taiho Oncology
Regulatory submission: NDA submitted February 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Pharmacology

Pharmacokinetics

2 evidence topics · 2 sources

Pharmacokinetics

“The elimination half-life of zipalertinib is 3-4 hours after repeat twice-a-day dosing for 14 days.” (opens the source at this quote in a new tab)

Time to peak concentration after fasting administration

“(Tmax) was in the range of 0.5-1.5 hours” (opens the source at this quote in a new tab)